Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology
作者： Christina Alidousty , Till Baar , Carina Heydt , Svenja Wagener-Ryczek , Anna Kron
关键词:
摘要: One distinct molecular subtype of non-small cell lung cancer (NSCLC) is defined by rearrangement the anaplastic lymphoma kinase (ALK). The increasing knowledge over last years has enabled continuous improvement ALK inhibitors; however, resistance in these patients remains a major concern. In this review, we summarize recent findings ALK+-adenocarcinoma lung, highlighting role TP53 mutations specific type and suggest new diagnostic strategies for future, order to improve patient's outcome.
amegroups.com参考文章(39)
Vishal Boolell, Muhammad Alamgeer, David Watkins, Vinod Ganju, The Evolution of Therapies in Non-Small Cell Lung Cancer Cancers. ,vol. 7, pp. 1815- 1846 ,(2015) , 10.3390/CANCERS7030864
B Solomon, K D Wilner, A T Shaw, Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clinical Pharmacology & Therapeutics. ,vol. 95, pp. 15- 23 ,(2013) , 10.1038/CLPT.2013.200
Hyeong Ryul Kim, Woo Sung Kim, Yun Jung Choi, Chang Min Choi, Jin Kyung Rho, Jae Cheol Lee, Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Molecular Oncology. ,vol. 7, pp. 1093- 1102 ,(2013) , 10.1016/J.MOLONC.2013.08.001
Gerald E. Stoica, Angera Kuo, Ciaran Powers, Emma T. Bowden, Elaine Buchert Sale, Anna T. Riegel, Anton Wellstein, Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types Journal of Biological Chemistry. ,vol. 277, pp. 35990- 35998 ,(2002) , 10.1074/JBC.M205749200
Toshinori Iwahara, Jiro Fujimoto, Duanzhi Wen, Rod Cupples, Nathan Bucay, Tsutomu Arakawa, Shigeo Mori, Barry Ratzkin, Tadashi Yamamoto, Molecular Characterization of ALK, a Receptor Tyrosine Kinase Expressed Specifically in the Nervous System Oncogene. ,vol. 14, pp. 439- 449 ,(1997) , 10.1038/SJ.ONC.1200849
Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Satoko Hatano, Hironori Ninomiya, Noriko Motoi, Ming-yon Mun, Yukinori Sakao, Sakae Okumura, Ken Nakagawa, Manabu Soda, Young Lim Choi, Hiroyuki Mano, Yuichi Ishikawa, EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Modern Pathology. ,vol. 22, pp. 508- 515 ,(2009) , 10.1038/MODPATHOL.2009.2
D. Ross Camidge, Robert C. Doebele, Treating ALK-positive lung cancer—early successes and future challenges Nature Reviews Clinical Oncology. ,vol. 9, pp. 268- 277 ,(2012) , 10.1038/NRCLINONC.2012.43
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka, Masashi Bando, Shoji Ohno, Yuichi Ishikawa, Hiroyuki Aburatani, Toshiro Niki, Yasunori Sohara, Yukihiko Sugiyama, Hiroyuki Mano, None, Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer Nature. ,vol. 448, pp. 561- 566 ,(2007) , 10.1038/NATURE05945
Aline Bennasroune, Pierre Mazot, Marie-Claude Boutterin, Marc Vigny, Activation of the orphan receptor tyrosine kinase ALK by zinc. Biochemical and Biophysical Research Communications. ,vol. 398, pp. 702- 706 ,(2010) , 10.1016/J.BBRC.2010.07.004
Cheng Ji, Li Zhang, Yan Cheng, Raj Patel, Hao Wu, Yi Zhang, Mian Wang, Shundong Ji, Chandra P Belani, Jin-Ming Yang, Xingcong Ren, None, Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer Biology & Therapy. ,vol. 15, pp. 570- 577 ,(2014) , 10.4161/CBT.28162